Ezra has launched its AI-powered full-body MRI screening service in the UK – marking a major expansion beyond the US.
The next-generation AI-powered screening solution is now available in London, with plans for a nationwide roll out throughout 2025.
As part of the UK launch, Ezra has partnered with Alliance Medical, the independent provider of diagnostic imaging services.
Alliance Medical will offer Ezra’s full-body MRI scans at its Marylebone clinic, with additional locations to follow.
The partnership ensures that Ezra’s AI-driven cancer screening benefits from established clinical expertise and a trusted diagnostic network, making advanced early detection more widely accessible.
Emi Gal, CEO and founder of Ezra, said: “Having witnessed the impact of late-stage cancer diagnosis in my own family, I understand the critical importance of early detection.
“Our mission is to make comprehensive cancer screening fast, accurate and affordable.”
Ezra’s AI-powered platform enhances MRI-based cancer screening by significantly reducing scan times, improving clinical workflow efficiencies, and providing an innovative E-SCORE system to help prioritise findings.
The service is designed to detect cancer and other serious health conditions early, scanning 13 organs using non-contrast MRI technology, including the brain, liver, kidneys, prostate, uterus, and spine, all in a single 60-minute session.
Cancer Research UK reports a 24 per cent increase in cancer diagnoses among people in their 40s and 50s since 1995.
Despite advances in treatment, nearly half of all cancer cases in the UK are still diagnosed at late stages, limiting treatment options and outcomes.
Ezra’s mission is to shift this dynamic by making AI-powered early screening more accessible to individuals who may benefit from proactive monitoring, including those with a family history of cancer or other risk factors.
Peter Winchester, Managing Director of Alliance Medical UK, said: “We are delighted to introduce full-body MRI screening in partnership with Ezra.
Its AI-driven approach represents the future of early cancer detection, and we are excited to integrate this technology into our imaging services to enhance diagnostic precision and accessibility.”
